Asia stocks surge as tech extends rebound, Dec rate cut bets grow
Investing.com - Cantor Fitzgerald raised its price target on CVRx Inc (NASDAQ:CVRX) to $13.00 from $11.00 on Monday, while maintaining an Overweight rating on the stock. The new target represents a 33% upside from the current price of $9.80, aligning with InvestingPro analysis that suggests the company is currently undervalued.
The price target increase follows CVRx ’s third-quarter 2025 financial results, which showed revenue of $14.7 million, representing year-over-year growth of approximately 10%. This performance exceeded both Cantor’s estimate of $14.5 million and the FactSet consensus of $14.1 million. The company’s trailing twelve-month revenue growth stands at an impressive 18.44%, with a robust gross profit margin of 84.49%.
U.S. Heart Failure revenue reached $13.5 million in the quarter, also showing year-over-year growth of approximately 10%. The company reported 250 active implanting centers at the end of the quarter, an increase of 10 centers sequentially.
Cantor Fitzgerald cited recent reimbursement wins, a more experienced sales force, and improving manufacturing efficiencies as factors that could drive future growth for CVRx.
The research firm stated it came away "incrementally positive" following the third-quarter results, noting that CVRx had narrowed its guidance for the remainder of the year. The stock has shown strong momentum with a 103.56% price return over the last six months, despite being down 23.36% year-to-date.
In other recent news, CVRx Inc. reported its third-quarter 2025 financial results, showing a revenue of $14.7 million. This represents a 10% year-over-year growth and exceeded both Canaccord Genuity’s estimate of $14.3 million and consensus expectations of $14.2 million. The company’s earnings per share (EPS) was reported at a loss of $0.49, which was slightly better than the anticipated loss of $0.50. Following these results, Canaccord Genuity raised its price target for CVRx to $11.00 from $9.00, maintaining a Buy rating on the stock. U.S. revenue for the company reached $13.5 million, slightly ahead of the firm’s projection of $13.4 million. Despite these positive earnings and revenue figures, the company’s stock experienced a decline in after-hours trading. The stock price decreased by 2% in aftermarket trading, closing at $9.99. These developments highlight the mixed reactions from the market despite the financial outperformance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.